Natixis Advisors LLC Reduces Position in Hologic, Inc. (NASDAQ:HOLX)

Natixis Advisors LLC trimmed its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 7.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 314,046 shares of the medical equipment provider’s stock after selling 24,878 shares during the quarter. Natixis Advisors LLC owned 0.14% of Hologic worth $22,639,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. State Street Corp increased its holdings in Hologic by 0.8% in the third quarter. State Street Corp now owns 10,409,327 shares of the medical equipment provider’s stock valued at $847,944,000 after buying an additional 81,057 shares during the last quarter. FMR LLC grew its holdings in shares of Hologic by 64.0% during the third quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock valued at $453,940,000 after purchasing an additional 2,174,093 shares during the last quarter. Victory Capital Management Inc. grew its holdings in shares of Hologic by 0.5% during the fourth quarter. Victory Capital Management Inc. now owns 4,917,551 shares of the medical equipment provider’s stock valued at $354,506,000 after purchasing an additional 24,358 shares during the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Hologic by 0.7% during the third quarter. The Manufacturers Life Insurance Company now owns 2,554,032 shares of the medical equipment provider’s stock valued at $208,051,000 after purchasing an additional 18,774 shares during the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its holdings in shares of Hologic by 8.6% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,466,888 shares of the medical equipment provider’s stock valued at $200,952,000 after purchasing an additional 195,285 shares during the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Jefferies Financial Group assumed coverage on Hologic in a report on Tuesday, December 10th. They set a “hold” rating and a $85.00 target price for the company. Raymond James reiterated an “outperform” rating and set a $90.00 price objective (down from $95.00) on shares of Hologic in a research report on Thursday, February 6th. William Blair reiterated an “outperform” rating on shares of Hologic in a research report on Thursday, February 6th. Argus downgraded Hologic from a “buy” rating to a “hold” rating in a research report on Monday, March 3rd. Finally, Royal Bank of Canada reduced their price objective on Hologic from $88.00 to $85.00 and set a “sector perform” rating for the company in a research report on Thursday, February 6th. Eleven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $84.62.

Hologic Stock Performance

HOLX opened at $61.82 on Tuesday. The business has a fifty day simple moving average of $66.94 and a 200-day simple moving average of $74.51. The firm has a market cap of $13.87 billion, a PE ratio of 19.50, a P/E/G ratio of 2.14 and a beta of 0.97. Hologic, Inc. has a fifty-two week low of $59.55 and a fifty-two week high of $84.67. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX) last released its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. As a group, equities analysts predict that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.